Biocoat Launches HYDAK® UV

The New Version of its Original HYDAK® Coating is Designed to be Cured Using Ultraviolet (UV) Light, Allowing for Flexible Integration with industry-standard UV Coating Systems

Biocoat reports the innovative coating is built on the proven bi-laminar platform that is used in Biocoat’s existing thermal heat cure coating technology.

“Biocoat is the only hydrophilic coating provider that can provide industry-leading performance in lubricity, durability, and particulates for both UV and thermal hydrophilic coatings,” said Dr. Bob Hergenrother, Biocoat’s Senior Director of Research & Development. “Our proprietary, internally developed UV coatings are built on the same bi-laminar coating platform currently being used on leading neurovascular, cardiovascular, and ophthalmic devices in over 160 countries around the world.”

“Biocoat is at the forefront of developing coating solutions to meet the increasing demands of our customers who are developing cutting-edge medical devices.  The introduction of HYDAK® UV positions Biocoat as the premier provider of hydrophilic coatings,” said Jim Moran, Biocoat’s President, and CEO.  “By working directly with our customers to understand their needs, we’ve developed a UV coating that maximizes device performance, and we’ve designed a manufacturing process that allows them to use their current in-house equipment. In addition, Biocoat will extend our in-house coating services to offer both UV and Thermal Coating Services.”

Scott Cramer, Chairman of Biocoat added, “We believe that the future growth of Biocoat will be a direct result of simplifying the development process for our customers.  The introduction of HYDAK® UV and the launch of the Contract Coating Services Unit were strategic initiatives specifically designed to improve Biocoat’s complete service offering.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version